Received Oct 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Injection site hot; injection site pain; sick first fay; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site warmth in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, less than a day after receiving Shingrix, the patient experienced injection site warmth (Verbatim: Injection site hot), injection site pain (Verbatim: injection site pain) and sickness (Verbatim: sick first fay). The outcome of the injection site warmth, injection site pain and sickness were not reported. It was unknown if the reporter considered the injection site warmth, injection site pain and sickness to be related to Shingrix. It was unknown if the company considered the injection site warmth, injection site pain and sickness to be related to Shingrix. Additional Information: GSK receipt date: 06-OCT-2025 This case was reported by a patient via interactive digital media. The batch number was not provided, and we are unable to contact the reporter.